These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 17972514)

  • 41. [Neoadjuvant chemotherapy for locally advanced gastric cancer].
    Kalmár K; Cseke L; Káposztás Z; Horváth G; Varga E
    Magy Seb; 2003 Oct; 56(5):177-84. PubMed ID: 15022621
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A phase I study of S-1 administration and a 24-h infusion of cisplatin plus paclitaxel in patients with advanced gastric cancer.
    Iwase H; Shimada M; Tsuzuki T; Okeya M; Kobayashi K; Hibino Y; Watanabe H; Goto H
    Anticancer Res; 2006; 26(2B):1605-9. PubMed ID: 16619579
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase II study of cisplatin, epirubicin and continuous infusion of 5-fluorouracil in patients with advanced intrahepatic cholangiocellular carcinoma (ICC).
    Takezako Y; Okusaka T; Ueno H; Ikeda M; Morizane C; Najima M
    Hepatogastroenterology; 2008; 55(85):1380-4. PubMed ID: 18795694
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Neoadjuvant chemotherapy for advanced gastric cancer using FLEP therapy].
    Mochizuki F; Fujii M; Kasakura Y; Kochi M; Imai S; Eguchi T; Tsuneda Y; Kanamori N; Kaiga T; Kobayashi M
    Gan To Kagaku Ryoho; 2000 Oct; 27(12):1812-5. PubMed ID: 11086418
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A multi-center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancer.
    Lee JJ; Kim SY; Chung HC; Lee KH; Song HS; Kang WK; Hong YS; Choi IS; Lee YY; Woo IS; Choi JH
    Cancer Chemother Pharmacol; 2009 May; 63(6):1083-90. PubMed ID: 18813927
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial.
    Cascinu S; Galizia E; Labianca R; Ferraù F; Pucci F; Silva RR; Luppi G; Beretta GD; Berardi R; Scartozzi M
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):37-43. PubMed ID: 20821330
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combination chemotherapy of S-1 and low-dose twice-weekly cisplatin for advanced and recurrent gastric cancer in an outpatient setting: a retrospective study.
    Tsuji A; Shima Y; Morita S; Uchida M; Okamoto K; Morita M; Horimi T; Shirasaka T
    Anticancer Res; 2008; 28(2B):1433-8. PubMed ID: 18505092
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Feasibility study of weekly paclitaxel as second-line chemotherapy against 5-FU-refractory gastric carcinoma].
    Ito S; Kodera Y; Mochizuki Y; Yamamura Y
    Gan To Kagaku Ryoho; 2005 Oct; 32(10):1427-30. PubMed ID: 16227742
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A phase II study of doxorubicin, cisplatin, and 5-fluorouracil in patients with advanced adenocarcinoma of the stomach or esophagus.
    Kulke MH; Wu B; Clark JW; Enzinger PC; Lynch TJ; Vincitore M; Michelini A; Fuchs CS
    Cancer Invest; 2006; 24(3):229-34. PubMed ID: 16809148
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biweekly oxaliplatin, fluorouracil and leucovorin versus cisplatin, fluorouracil and leucovorin in patients with advanced gastric cancer.
    Popov I; Radosevic-Jelic L; Jezdic S; Milovic M; Borojevic N; Stojanovic S; Stankovic V; Josifovski T; Kezic I
    J BUON; 2008; 13(4):505-11. PubMed ID: 19145671
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase II study of mitomycin C, cisplatin and 5-fluorouracil for advanced and recurrent gastric cancer.
    Kikuyama S; Inada T; Oyama R; Ogata Y
    Anticancer Res; 2002; 22(6B):3633-6. PubMed ID: 12552968
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Correlative analysis between serum dihydropyrimidine dehydrogenase, activity, concentration of 5-fluorouracil and adverse events in the treatment of advanced gastric cancer patients].
    Peng RJ; Dong QM; Shi YX; Cao Y; Zhou ZM; Yuan ZY; Li S; Li H; Jiang WQ
    Ai Zheng; 2006 Aug; 25(8):1039-43. PubMed ID: 16965690
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Epirubicin combined with DDP and 5-Fu for treatment of advanced gastric cancer].
    Lu M; Shen L; Li J; Li Y; Zhang XD
    Zhonghua Zhong Liu Za Zhi; 2009 May; 31(5):392-5. PubMed ID: 19799092
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pemetrexed and cisplatin in patients with advanced gastric cancer: a Korean cancer study group multicenter phase II study.
    Kim YH; Chung HC; Kang WK; Park SR; Kim CS; Kim TY; Shin SW; Park BJ; Cha SJ; Bang YJ
    Cancer Chemother Pharmacol; 2008 Jul; 62(2):263-70. PubMed ID: 17960386
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Renal toxicity of adjuvant chemoradiotherapy with cisplatin in gastric cancer.
    Welz S; Hehr T; Kollmannsberger C; Bokemeyer C; Belka C; Budach W
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1429-35. PubMed ID: 17692474
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Prospective non-randomized study of chemotherapy combined with radiotherapy versus chemotherapy alone in patients with metastatic or relapsed esophageal squamous cell carcinoma].
    Zhang XD; Shen L; Li J; Li Y; Li J; Zhang XT; Jin ML
    Zhonghua Zhong Liu Za Zhi; 2007 Jun; 29(6):474-7. PubMed ID: 17974288
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of intermittent 5-fluorouracil and low-dose cisplatin therapy on advanced and recurrent gastric cancer.
    Kanetaka K; Enjoji A; Furui J; Nagata Y; Fujioka H; Shiogama T; Miyata A; Kishikawa H; Matsuo S; Iwata T; Kanematsu T; Eguchi S;
    Anticancer Res; 2012 Aug; 32(8):3495-9. PubMed ID: 22843936
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Optimal dose-finding study of bi-weekly paclitaxel in unresectable advanced or recurrent gastric cancer.
    Koizumi W; Tanabe S; Higuchi K; Sasaki T; Nakayama S; Nakatani K; Nishimura K; Shimoda T; Azuma M; Ishido K; Saigenji K
    Anticancer Res; 2006; 26(5B):3797-802. PubMed ID: 17094404
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric Cancer (CCOG0302 study).
    Kodera Y; Ito S; Mochizuki Y; Fujitake S; Koshikawa K; Kanyama Y; Matsui T; Kojima H; Takase T; Ohashi N; Fujiwara M; Sakamoto J; Akimasa N;
    Anticancer Res; 2007; 27(4C):2667-71. PubMed ID: 17695430
    [TBL] [Abstract][Full Text] [Related]  

  • 60. TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin.
    Kim JG; Sohn SK; Chae YS; Song HS; Kwon KY; Do YR; Kim MK; Lee KH; Hyun MS; Lee WS; Sohn CH; Jung JS; Kim GC; Chung HY; Yu W
    Cancer Chemother Pharmacol; 2009 Jul; 64(2):355-60. PubMed ID: 19052714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.